Peritoneal tumor carcinomatosis: Pharmacological targeting with hyaluronan-based bioconjugates overcomes therapeutic indications of current drugs

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Montagner, Isabella Monia ^a   Merlo, Anna ^a   Zuccolotto, Gaia ^b   Renier, Davide ^c   Campisi, Monica ^c   Pasut, Gianfranco ^b   Zanovello, Paola ^a,b   Rosato, Antonio ^a,b  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c Fidia Advanced Biopolymers   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CAVEOLIN; DNA TOPOISOMERASE; FIRTECAN; HERMES ANTIGEN; HYALURONIC ACID; IRINOTECAN; PACLITAXEL; ANTINEOPLASTIC AGENT; DRUG CARRIER; HYALURONAN-MEDIATED MOTILITY RECEPTOR; SCLEROPROTEIN;

ANIMAL EXPERIMENT; ARTICLE; BIOLUMINESCENCE; CARCINOMATOUS PERITONITIS; COLORECTAL CANCER; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; CYTOTOXICITY ASSAY; DRUG EFFICACY; DRUG TARGETING; DRUG TOLERABILITY; ENDOCYTOSIS; FEMALE; FLUORESCENCE IMAGING; IN VITRO STUDY; IN VIVO STUDY; LOCAL RECURRENCE FREE SURVIVAL; LYSOSOME; MOUSE; NONHUMAN; STOMACH CANCER; TUMOR CELL; TUMOR GROWTH; TUMOR XENOGRAFT; ANIMAL; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; PATHOLOGY; PERITONEAL NEOPLASMS; TUMOR CELL LINE;

MUS;

ANIMALS; ANTIGENS, CD44; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG CARRIERS; EXTRACELLULAR MATRIX PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYALURONIC ACID; MICE; PERITONEAL NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84911375720     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0112240     Document Type: Article

References (55)

1. Walker AS, Zwintscher NP, Johnson EK, Maykel JA, Stojadinovic A, et al. (2014) Future directions for monitoring treatment response in colorectal cancer. J Cancer 5: 44-57.
2. Correa P (2013) Gastric cancer: Overview. Gastroenterol Clin North Am 42: 211-217.
3. Elias D, Quenet F, Goere D (2012) Current status and future directions in the treatment of peritoneal dissemination from colorectal carcinoma. Surg Oncol Clin N Am 21: 611-623.
4. Glockzin G, Piso P (2012) Current status and future directions in gastric cancer with peritoneal dissemination. Surg Oncol Clin N Am 21: 625-633.
5. Bozzetti F, Yu W, Baratti D, Kusamura S, Deraco M (2008) Locoregional treatment of peritoneal carcinomatosis from gastric cancer. J Surg Oncol 98: 273-276.
6. Schweigert M, Dubecz A, Stein HJ (2013) Oesophageal cancer-an overview. Nat Rev Gastroenterol Hepatol 10: 230-244.
7. Gros SJ, Dohrmann T, Rawnaq T, Kurschat N, Bouvet M, et al. (2010) Orthotopic fluorescent peritoneal carcinomatosis model of esophageal cancer. Anticancer Res 30: 3933-3938.
8. Coccolini F, Gheza F, Lotti M, Virzi S, Iusco D, et al. (2013) Peritoneal carcinomatosis. World J Gastroenterol 19: 6979-6994.
9. Brucher BL, Piso P, Verwaal V, Esquivel J, Derraco M, et al. (2012) Peritoneal carcinomatosis: Cytoreductive surgery and HIPEC-overview and basics. Cancer Invest 30: 209-224.
10. Konigsrainer I, Beckert S (2012) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Where are we? World J Gastroenterol 18: 5317-5320.
11. Serafino A, Zonfrillo M, Andreola F, Psaila R, Mercuri L, et al. (2011) CD44-targeting for antitumor drug delivery: A new SN-38-hyaluronan bioconjugate for locoregional treatment of peritoneal carcinomatosis. Curr Cancer Drug Targets 11: 572-585.
12. st century: The end of the beginning. Adv Drug Deliv Rev 65: 60-70.
13. Varshosaz J (2012) Dextran conjugates in drug delivery. Expert Opin Drug Deliv 9: 509-523.
14. Sugahara S, Kajiki M, Kuriyama H, Kobayashi TR (2007) Complete regression of xenografted human carcinomas by a paclitaxel-carboxymethyl dextran conjugate (AZ10992). J Control Release 117: 40-50.
15. Northfelt DW, Allred JB, Liu H, Hobday TJ, Rodacker MW, et al. (2012) Phase 2 trial of paclitaxel polyglumex with capecitabine for metastatic breast cancer. Am J Clin Oncol.
16. Jain JP, Chitkara D, Kumar N (2008) Polyanhydrides as localized drug delivery carrier: An update. Expert Opin Drug Deliv 5: 889-907.
17. Nakamura H, Etrych T, Chytil P, Ohkubo M, Fang J, et al. (2014) Two step mechanisms of tumor selective delivery of N-(2-hydroxypropyl)methacrylamide copolymer conjugated with pirarubicin via an acid-cleavable linkage. J Control Release 174: 81-87.
18. Larson N, Yang J, Ray A, Cheney DL, Ghandehari H, et al. (2013) Biodegradable multiblock poly(N-2-hydroxypropyl)methacrylamide gemcitabine and paclitaxel conjugates for ovarian cancer cell combination treatment. Int J Pharm 454: 435-443.
19. Patnaik A, Papadopoulos KP, Tolcher AW, Beeram M, Urien S, et al. (2013) Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer. Cancer Chemother Pharmacol 71: 1499-1506.
20. Clementi C, Miller K, Mero A, Satchi-Fainaro R, Pasut G (2011) Dendritic poly(ethylene glycol) bearing paclitaxel and alendronate for targeting bone neoplasms. Mol Pharm 8: 1063-1072.
21. Rosato A, Banzato A, De Luca G, Renier D, Bettella F, et al. (2006) HYTAD1-p20: A new paclitaxel-hyaluronic acid hydrosoluble bioconjugate for treatment of superficial bladder cancer. Urol Oncol 24: 207-215.
22. Laurent TC, Fraser JR (1992) Hyaluronan. FASEB J 6: 2397-2404.
23. Liao YH, Jones SA, Forbes B, Martin GP, Brown MB (2005) Hyaluronan: Pharmaceutical characterization and drug delivery. Drug Deliv 12: 327-342.
24. Entwistle J, Hall CL, Turley EA (1996) HA receptors: Regulators of signalling to the cytoskeleton. J Cell Biochem 61: 569-577.
25. Isacke CM, Yarwood H (2002) The hyaluronan receptor, CD44. Int J Biochem Cell Biol 34: 718-721.
26. Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Seed B (1990) CD44 is the principal cell surface receptor for hyaluronate. Cell 61: 1303-1313.
27. Zhou B, McGary CT, Weigel JA, Saxena A, Weigel PH (2003) Purification and molecular identification of the human hyaluronan receptor for endocytosis. Glycobiology 13: 339-349.
28. Takaishi S, Okumura T, Tu S, Wang SS, Shibata W, et al. (2009) Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells 27: 1006-1020.
29. Zhao JS, Li WJ, Ge D, Zhang PJ, Li JJ, et al. (2011) Tumor initiating cells in esophageal squamous cell carcinomas express high levels of CD44. PLoS One 6: e21419.
30. Oommen OP, Garousi J, Sloff M, Varghese OP (2013) Tailored doxorubicinhyaluronan conjugate as a potent anticancer glyco-drug: An alternative to prodrug approach. Macromol Biosci.
31. Sorbi C, Bergamin M, Bosi S, Dinon F, Aroulmoji V, et al. (2009) Synthesis of 6- O-methotrexylhyaluronan as a drug delivery system. Carbohydr Res 344: 91-97.
32. Dong Z, Zheng W, Xu Z, Yin Z (2013) Improved stability and tumor targeting of 5-fluorouracil by conjugation with hyaluronan. J Appl Polym Sci 130: 927-32.
33. Banzato A, Bobisse S, Rondina M, Renier D, Bettella F, et al. (2008) A paclitaxel-hyaluronan bioconjugate targeting ovarian cancer affords a potent in vivo therapeutic activity. Clin Cancer Res 14: 3598-3606.
34. Jaganathan SK, Supriyanto E, Mandal M (2013) Events associated with apoptotic effect of p-coumaric acid in HCT-15 colon cancer cells. World J Gastroenterol 19: 7726-7734.
35. Faryammanesh R, Lange T, Magbanua E, Haas S, Meyer C, et al. (2014) SDA, a DNA aptamer inhibiting E- and P-selectin mediated adhesion of cancer and leukemia cells, the first and pivotal step in transendothelial migration during metastasis formation. PLoS One 9: e93173.
36. Kumar SS, Price TJ, Mohyieldin O, Borg M, Townsend A, et al. (2014) KRAS G13D mutation and sensitivity to cetuximab or panitumumab in a colorectal cancer cell line model. Gastrointest Cancer Res 7: 23-26.
37. Smit JK, Faber H, Niemantsverdriet M, Baanstra M, Bussink J, et al. (2013) Prediction of response to radiotherapy in the treatment of esophageal cancer using stem cell markers. Radiother Oncol 107: 434-441.
38. Yuan Y, Chen H, Ma G, Cao X, Liu Z (2012) Reelin is involved in transforming growth factor-beta1-induced cell migration in esophageal carcinoma cells. PLoS One 7: e31802.
39. Aoyagi K, Kouhuji K, Miyagi M, Kizaki J, Isobe T, et al. (2013) Molecular targeting therapy using bevacizumab for peritoneal metastasis from gastric cancer. World J Crit Care Med 2: 48-55.
40. Montagner IM, Banzato A, Zuccolotto G, Renier D, Campisi M, et al. (2013) Paclitaxel-hyaluronan hydrosoluble bioconjugate: Mechanism of action in human bladder cancer cell lines. Urol Oncol 31: 1261-1269.
41. Crouch SP, Kozlowski R, Slater KJ, Fletcher J (1993) The use of ATP bioluminescence as a measure of cell proliferation and cytotoxicity. J Immunol Methods 160: 81-88.
42. Keyaerts M, Verschueren J, Bos TJ, Tchouate-Gainkam LO, Peleman C, et al. (2008) Dynamic bioluminescence imaging for quantitative tumour burden assessment using IV or IP administration of D: -Luciferin: Effect on intensity, time kinetics and repeatability of photon emission. Eur J Nucl Med Mol Imaging 35: 999-1007.
43. Contreras-Ruiz L, de la Fuente M, Parraga JE, Lopez-Garcia A, Fernandez I, et al. (2011) Intracellular trafficking of hyaluronic acid-chitosan oligomer-based nanoparticles in cultured human ocular surface cells. Mol Vis 17: 279-290.
44. Dodds HM, Haaz MC, Riou JF, Robert J, Rivory LP (1998) Identification of a new metabolite of CPT-11 (irinotecan): Pharmacological properties and activation to SN-38. J Pharmacol Exp Ther 286: 578-583.
45. Al-Shammaa HA, Li Y, Yonemura Y (2008) Current status and future strategies of cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. World J Gastroenterol 14: 1159-1166.
46. Elias D, Gilly F, Boutitie F, Quenet F, Bereder JM, et al. (2010) Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: Retrospective analysis of 523 patients from a multicentric french study. J Clin Oncol 28: 63-68.
47. Gill RS, Al-Adra DP, Nagendran J, Campbell S, Shi X, et al. (2011) Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC: A systematic review of survival, mortality, and morbidity. J Surg Oncol 104: 692-698.
48. Passot G, Bakrin N, Roux AS, Vaudoyer D, Gilly FN, et al. (2013) Quality of life after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy: A prospective study of 216 patients. Eur J Surg Oncol.
49. Glockzin G, Schlitt HJ, Piso P (2009) Peritoneal carcinomatosis: Patients selection, perioperative complications and quality of life related to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Surg Oncol 7: 5-7819-7-5.
50. Lu Z, Wang J, Wientjes MG, Au JL (2010) Intraperitoneal therapy for peritoneal cancer. Future Oncol 6: 1625-1641.
51. De Smet L, Ceelen W, Remon JP, Vervaet C (2013) Optimization of drug delivery systems for intraperitoneal therapy to extend the residence time of the chemotherapeutic agent. ScientificWorldJournal 2013: 720858.
52. Bassi PF, Volpe A, D'Agostino D, Palermo G, Renier D, et al. (2011) Paclitaxelhyaluronic acid for intravesical therapy of bacillus calmette-guerin refractory carcinoma in situ of the bladder: Results of a phase I study. J Urol 185: 445-449.
53. Authier N, Gillet JP, Fialip J, Eschalier A, Coudore F (2001) Assessment of neurotoxicity following repeated cremophor/ethanol injections in rats. Neurotox Res 3: 301-306.
54. Gelderblom H, Verweij J, Nooter K, Sparreboom A (2001) Cremophor EL: The drawbacks and advantages of vehicle selection for drug formulation. Eur -J Cancer 37: 1590-1598.
55. Pucciarelli S, Codello L, Rosato A, Del Bianco P, Vecchiato G, et al. (2003) Effect of antiadhesive agents on peritoneal carcinomatosis in an experimental model. Br J Surg 90: 66-71.